• Home The study will enroll to 25 patients with metastatic malignancy up.

The study will enroll to 25 patients with metastatic malignancy up.

Aethlon receives authorization to begin Hemopurifier study at Sarcoma Oncology Center Aethlon Medical, Inc. The study will enroll to 25 patients with metastatic malignancy up, including those with non-small cell lung malignancy, prostate cancer, melanoma, head and neck cancer, and sarcoma.Tumor-secreted exosomes, which are not addressed by drug therapy, assist cancerous tumors in evading the immune response and so are implicated in the survival, growth, and metastasis of cancer Click to see more .

– May 17, 2010: Publication of an article in the May 12, 2010 issue of the Journal of the National Cancer tumor Institute, entitled ‘In Vitro and In Vivo Inhibition of Neuroblastoma Tumor Cell Growth by Akt Inhibitor Perifosine,’ demonstrating the single agent activity of perifosine in neuroblastoma tumor preclinical versions. June 7 -, 2010: Presentation at the American Culture of Clinical Oncology annual meeting of Stage 1 data on one agent perifosine in the treating recurrent pediatric solid tumors, including patients with advanced mind neuroblastoma and tumors.